Die Vaccinex-Aktie steht als kleine US-Biotech-Position für hohes Risiko: schwache historische Ergebnisse treffen auf einen engen Kursrahmen und eine geringe Marktkapitalisierung. Für Anleger zählt, wie lange die Finanzierung reicht und welche Pipeline-Chancen realistisch sind.

Vaccinex (NASDAQ:VCNX – Get Free Report) is projected to announce its resultson Monday, August 10th. Analysts expect Vaccinex to post earnings of ($73.0380) per share and revenue of $0.63 million for the quarter. Vaccinex Price Performance Shares of NASDAQ VCNX opened at $0.99 on Friday. The company has a market cap of $2.57 million, a [...]

Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s stock price shot up 9.9% on Thursday . The company traded as high as $0.83 and last traded at $0.83. 161 shares were traded during mid-day trading, a decline of 100% from the average session volume of 57,098 shares. The stock had previously closed at $0.76. Vaccinex Trading […]

Reported Tuesday, Dec 23 - 8:16am EST (TheFly subscription required to read more.)

Reported Tuesday, May 27 - 8:49am EDT (TheFly subscription required to read more.)

Reported Monday, Apr 21 - 8:53am EDT (TheFly subscription required to read more.)

Reported Friday, Mar 7 - 5:21pm EST (TheFly subscription required to read more.)

Vaccinex (OTCMKTS: VCNX) reported it released its 2025 annual financial results for the year ended December 31, 2025 and posted the financial statements on its website on April 29, 2026. The company is a clinical-stage developer of investigational antibody therapies for Alzheimer’s, Huntington’s, and cancer.

Vaccinex (NASDAQ:VCNX) announced a $60 million revenue‑sharing financing with Pepinemab Development Venture LP to fund an enlarged Phase 2b trial of pepinemab for Alzheimer’s disease on Dec 23, 2025. The deal gives PDV 50% of future economic proceeds from neurological pepinemab licenses and 25% for other indications. Company cites prior SIGNAL‑AD Phase 1/2a and HD Phase 2 data showing tolerability, biomarker effects, reduced Ast10 astrocyte representation, and signals of slowed cognitive decline; results were reported at CTAD on Dec 3, 2025.

Biotech firm faces voluntary delisting by March 2025 but maintains focus on Alzheimer's and cancer drug development through alternative funding sources.

Vaccinex (VCNX) set to be delisted from Nasdaq following failure to maintain $2.5M stockholders' equity requirement. Trading suspension effective Dec 18, moving to OTC Markets.

Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal means stepping outside the world of drug development. Now, the company is further divesting itself from biotech, selling its cardiovascular pipeline to Seismic Pharmaceutical Holdings.